<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00608881</url>
  </required_header>
  <id_info>
    <org_study_id>2CARE 01.00</org_study_id>
    <secondary_id>5U01NS052592</secondary_id>
    <secondary_id>5R01NS052619</secondary_id>
    <nct_id>NCT00608881</nct_id>
  </id_info>
  <brief_title>Coenzyme Q10 in Huntington's Disease (HD)</brief_title>
  <acronym>2CARE</acronym>
  <official_title>Coenzyme Q10 in Huntington's Disease (HD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goals of this trial are to determine if coenzyme Q10 is effective in slowing the
      worsening symptoms of Huntington's disease and to learn about the safety and acceptability of
      long-term coenzyme Q10 use by determining its effects on people with Huntington's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Huntington's disease (HD) is a slowly progressive disorder that devastates the lives of those
      affected and their families. There are no treatments that slow the progression of HD, only
      mildly effective symptomatic therapies are available.

      The purpose of this trial is to find out if coenzyme Q10 (CoQ) is effective in slowing the
      worsening symptoms of HD. In this study, researchers also will learn about the safety and
      acceptability of long-term CoQ use by determining its effects on people with HD.

      Participants in this trial will be randomly chosen to one of two groups. Group 1 will receive
      CoQ (2400 mg/day), and group 2 will receive a placebo (an inactive substance). Researchers
      will compare the change in total functional capacity (TFC)—a measure of functional
      disability—in the two groups. The TFC is a valid and reliable measure of disease progression
      and is particularly responsive to change in the early and mid-stages of HD. Researchers will
      also compare the changes in other components of the Unified Huntington's Disease Rating Scale
      '99 (UHDRS) including: the total motor score, total behavioral frequency score, total
      behavior frequency X severity score, verbal fluency test, symbol digit modalities test,
      Stroop, interference test, functional checklist, and independence scale scores. The groups
      will also be compared with respect to tolerability, adverse events, vital signs, and
      laboratory test results as measures of safety.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Futility analysis failed to showed likelihoo of benefit of CoQ 2400 mg/day.
  </why_stopped>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Joint Rank (Combination of Time to Death (for Subjects Who Died) and Change in Total Functional Capacity Score (TFC) From Baseline to Month 60 (for Subjects Who Survived))</measure>
    <time_frame>5 years</time_frame>
    <description>The primary outcome variable at the start of the trial was the change in TFC score from baseline to Month 60. The Data and Safety Monitoring Board recommended to the trial leadership that they reconsider how they accommodate missing data from subjects who die in their primary analysis of the change in TFC score. Based on these recommendations, the trial leadership changed the primary analysis to that of a joint rank approach. TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Total Functional Capacity (TFC) Score From Baseline to Month 60</measure>
    <time_frame>Baseline and Month 60</time_frame>
    <description>TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Checklist Score From Baseline to Month 60</measure>
    <time_frame>Baseline and Month 60</time_frame>
    <description>The functional assessment checklist includes 25 questions about common daily tasks. A score of 1 is given for each &quot;yes&quot; reply and a score of 0 is given for each &quot;no&quot; reply (scale range is 0-25). Higher scores indicate better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Independence Scale Score From Baseline to Month 60</measure>
    <time_frame>Baseline and Month 60</time_frame>
    <description>The independence scale assesses independence on a 0 to 100 scale with higher scores indicating better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Motor Score From Baseline to Month 60</measure>
    <time_frame>Baseline and Month 60</time_frame>
    <description>The motor section of the Unified Huntington's Disease Rating Scale (UHDRS) assesses motor features of Huntington disease with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor score is the sum of all the individual motor ratings, with higher scores (124) indicating more severe motor impairment than lower scores. The score ranges from 0 to 124.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Behavioral Frequency Score From Baseline to Month 60</measure>
    <time_frame>Baseline and Month 60</time_frame>
    <description>The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. A total score was calculated by summing up all the individual behavioral frequency items (range 0-56) with higher scores representing more severe behavioral impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Behavioral Frequency x Severity Score From Baseline to Month 60</measure>
    <time_frame>Baseline and Month 60</time_frame>
    <description>The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. The total score is the sum of the product of the individual behavioral frequency and severity items (range 0-176) with higher scores representing more severe behavioral impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Symbol Digit Modalities Test (SDMT) From Baseline to Month 60</measure>
    <time_frame>Baseline and Month 60</time_frame>
    <description>The SDMT assesses attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The score is the number of correctly paired abstract symbols and specific numbers in 90 seconds with higher scores indicating better cognitive functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Verbal Fluency Test From Baseline to Month 60</measure>
    <time_frame>Baseline and Month 60</time_frame>
    <description>The verbal fluency test is typically considered a measure of executive function. The score is the number of correct words produced across three 1-minute trials.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Stroop Interference Test - Color Naming From Baseline to Month 60</measure>
    <time_frame>Baseline and Month 60</time_frame>
    <description>Stroop Interference Test - color naming score is the total number of correct colors identified in 45 seconds and reflects processing speed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Stroop Interference Test - Word Reading From Baseline to Month 60</measure>
    <time_frame>Baseline and Month 60</time_frame>
    <description>Stroop Interference Test - word reading score is the total number of correct words read in 45 seconds and reflects processing speed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Stroop Interference Test - Interference From Baseline to Month 60</measure>
    <time_frame>Baseline and Month 60</time_frame>
    <description>Stroop Interference Test - interference score is the total number of correct items identified in 45 seconds and reflects an executive measure of inhibitory ability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to a Two-Point Decline in TFC Score or Death</measure>
    <time_frame>5 years</time_frame>
    <description>TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to a Three-Point Decline in TFC Score or Death</measure>
    <time_frame>5 years</time_frame>
    <description>TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number Completing Study at Assigned Dosage Level</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">609</enrollment>
  <condition>Huntington's Disease</condition>
  <arm_group>
    <arm_group_label>A - coenzyme Q10 2400 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized to active treatment (coenzyme Q10 2400 mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Randomized to placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>coenzyme Q10</intervention_name>
    <description>4 - 300 mg CoQ chewable wafers taken orally twice a day</description>
    <arm_group_label>A - coenzyme Q10 2400 mg/day</arm_group_label>
    <other_name>CoQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>an inactive substance</description>
    <arm_group_label>B - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be eligible for enrollment into this study, subjects must meet the following eligibility
        criteria within 28 days prior to randomization:

          -  Subjects must have clinical features of HD and a confirmed family history of HD, OR a
             CAG repeat expansion ≥ 36.

          -  TFC &gt; 9.

          -  Must be ambulatory and not require skilled nursing care.

          -  Age ≥ 16 years.

          -  Women must not be able to become pregnant (e.g., post menopausal, surgically sterile
             or using adequate birth control methods for the duration of the study).

          -  If psychotropic medications are taken (e.g., anxiolytics, hypnotics, benzodiazepines,
             antidepressants), they must be at a stable dosage for four weeks prior to
             randomization and should be maintained at a constant dosage throughout the study, as
             possible. (Note: stable dosing of tetrabenazine is allowable.) Any changes to these
             medications mandated by clinical conditions will be systematically recorded and the
             subject will be permitted to remain in the trial.

          -  Able to give informed consent and comply with trial procedures

          -  Able to take oral medication.

          -  May be required to identify an informant or caregiver who will be willing and able to
             supervise the daily dosing of study medications and to maintain control of study
             medications in the home.

          -  A designated individual will be identified by the subject to participate in the
             ongoing consent process should the subject's cognitive capacity to consent become
             compromised during participation in the study.

        Exclusion Criteria:

          -  History or known sensitivity of intolerability to CoQ.

          -  Exposure to any investigational drug within 30 days of the Baseline visit.

          -  Clinical evidence of unstable medical illness in the investigator's judgment.

          -  Unstable psychiatric illness defined as psychosis (hallucinations or delusions),
             untreated major depression or suicidal ideation within 90 days of the Baseline visit.

          -  Substance (alcohol or drug) abuse within one year of the Baseline visit.

          -  Women who are pregnant or breastfeeding.

          -  Use of supplemental coenzyme Q10 within 30 days prior to the Baseline visit

          -  Clinically serious abnormalities in the screening laboratory studies (Screening
             creatinine greater than 2.0, alanine aminotransferase (ALT) or total bilirubin greater
             than 3 times the upper limit of normal, absolute neutrophil count of ≤1000/ul,
             platelet concentration of &lt;100,000/ul, hematocrit level of &lt;33 for female or &lt;35 for
             male, or coagulation tests &gt; 1.5 time upper limit of normal).

          -  Known allergy to FD&amp;C yellow #5 or any other ingredient in the study drug (active and
             placebo)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merit Cudkowicz, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael McDermott, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester, Biostatistics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karl Kieburtz, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, Clinical Trials Coordination Center, University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama At Birmingham, Pediatric Neurology Childrens, Harbor Bldg Suite 314, 1600 7Th Avenue South</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233-1711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona, 13400 East Shea Boulevard, Csu-Cp21B</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WASHINGTON REGIONAL MEDICAL CENTER, 3215 N. North Hills Blvd</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Irvine, Department of Neurology, 100 Irvine Hall</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697-4275</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis, Medical Center Dept of Neurology, Acc Building Suite 3700, 4860 Y Street</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Neurological Institute, Movement Disorders Center, 701 East Hampden Avenue Suite 510</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Center for Movement Disorders and Neurorestoration, 3450 Hull Road, 4th Floor</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNIVERSITY OF MIAMI, 1150 NW 14th STREET, #401</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida, College of Medicine Dept of Neurology, 12901 Bruce B Downs Blvd Mdc-55</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University, Wesley Woods Center, 1841 Clifton Road NE Room 314</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Idaho Elks Rehabilitation Hospital, 600 North Robbins Road</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center, Department of Neurological Sciences, 1725 West Harrison Suite 755</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine, Outpatient Clinical Research Facility, 535 Barnhill Drive Room #150</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospital and Clinics, 200 Hawkins Road, Room W263 General Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center, Department of Neurology, 3599 Rainbow Blvd Mail Stop 2012</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160-7314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hereditary Neurological Disease Centre (Hndc),3223 N. Webb, Suite 4</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine, 22 South Greene Street, N4 W49-B</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University, 600 North Wolfe Street, Meyer 2-181</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University School of Medicine, Department of Neurology, 715 Albany Street C329</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital, 149 13Th Street Suite 2241</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan, 1500 E Medical Center Drive, B1 H202 Nuclear Medicine</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Struthers Parkinson'S Center, 6701 Country Club Drive</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55427</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine, Box 8111, 660 South Euclid</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Las Vegas School of Medicine, 1707 W. Charleston Blvd, Suite 220</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nj Neuroscience Institute, Jfk Medical Center, 65 James Street</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08818</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College, Parkinson'S Disease &amp; Movement Disorders Ctr</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore-Lij Health System, 350 Community Drive Room 110, Research Institute</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University, Sergievsky Center P&amp;S Box 16, 630 West 168Th Street</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester, Department of Neurology, 919 Westfall Road Building C Suite 220</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University, 932 Morreene Road #213</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University, Baptist Med Center, Department of Neurology, Medical Center Boulevard</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati/Cincinnati Children'S Hospital, 222 Piedmont Avenue, Suite 3200</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHIO STATE UNIVERSITY , 2006 Kenny Road</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ST. LUKE'S HOSPITAL, 240 Centronia Road</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Pennsylvania Hospital Department of Neurology , 330 South 9Th Street</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Kaufmann Medical Building, 3471 Fifth Avunue, Suite 811</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BUTLER HOSPTIAL MOVEMENT DISORDER PROGRAM, 345 Blackstone Boulevard</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Tennesee Health Science Cen, 855 Monroe Avenue, Department of Neurology, Room 415 Link Bldg</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UN oF TEXAS SOUTHWESTERN MED CENTER DALLAS, 5323 HARRY HINES BOULEVARD H1.108</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine, 6550 Fannin Suite 1801</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital, Department of Neurology Level 1, Po Box 533</name>
      <address>
        <city>Wentworthville</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary, Heritage Medical Research Clinic, Trw Bldg 5 Floor, 3280 Hospital Dri. NW</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta, Glenrose Rehab Hosp, Movement Disorder Clinic , Rm 0601 Gleneast 10230 - 111 Avenue</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5G 0B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medical Genetics, Ubc Hospital, Room S179-2211 Westbrook Mall</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre, University Hospital, 339 Windermere Road</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre For Movement Disorders, 2780 Bur Oak Avenue</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L4A 1G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NORTH YORK GENERAL HOSPITAL (2), 4001 Leslie Street</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M2K 1E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North York General Hospital, 4001 Leslie Street</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M2R 1N5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kowall N, Ferrante R, Martin J. Patterns of cell loss in Huntington's disease. Trends in Neurosciences 1987;10:24-29.</citation>
  </reference>
  <reference>
    <citation>Riley D, Lang A. Movement Disorders. In: Bradley W, Daroff R, Fenichel G, eds. Neurology in Clinical Practice. The Neurological Disorders. Boston: Butterworth-Heinemann, 1991: 1563-1601.</citation>
  </reference>
  <reference>
    <citation>Adams P, Falek A, Arnold J. Huntington disease in Georgia: age at onset. Am J Hum Genet. 1988 Nov;43(5):695-704.</citation>
    <PMID>2973230</PMID>
  </reference>
  <reference>
    <citation>Conneally PM. Huntington disease: genetics and epidemiology. Am J Hum Genet. 1984 May;36(3):506-26. Review.</citation>
    <PMID>6233902</PMID>
  </reference>
  <reference>
    <citation>Harper PS. The epidemiology of Huntington's disease. Hum Genet. 1992 Jun;89(4):365-76. Review.</citation>
    <PMID>1535611</PMID>
  </reference>
  <reference>
    <citation>Tanner CM, Goldman SM. Epidemiology of movement disorders. Curr Opin Neurol. 1994 Aug;7(4):340-5. Review.</citation>
    <PMID>7952243</PMID>
  </reference>
  <reference>
    <citation>Young AB, Shoulson I, Penney JB, Starosta-Rubinstein S, Gomez F, Travers H, Ramos-Arroyo MA, Snodgrass SR, Bonilla E, Moreno H, et al. Huntington's disease in Venezuela: neurologic features and functional decline. Neurology. 1986 Feb;36(2):244-9.</citation>
    <PMID>2935747</PMID>
  </reference>
  <reference>
    <citation>Bruyn G. Huntington's chorea: Historical clinical and laboratory synopsis. In: Vinken P, Bruyn G, eds. Handbook of Clinical Neurology. Amsterdam, 1968: 298-378.</citation>
  </reference>
  <reference>
    <citation>Leigh RJ, Newman SA, Folstein SE, Lasker AG, Jensen BA. Abnormal ocular motor control in Huntington's disease. Neurology. 1983 Oct;33(10):1268-75.</citation>
    <PMID>6225033</PMID>
  </reference>
  <reference>
    <citation>Caine ED, Hunt RD, Weingartner H, Ebert MH. Huntington's dementia. Clinical and neuropsychological features. Arch Gen Psychiatry. 1978 Mar;35(3):377-84.</citation>
    <PMID>153122</PMID>
  </reference>
  <reference>
    <citation>Bamford KA, Caine ED, Kido DK, Plassche WM, Shoulson I. Clinical-pathologic correlation in Huntington's disease: a neuropsychological and computed tomography study. Neurology. 1989 Jun;39(6):796-801.</citation>
    <PMID>2524678</PMID>
  </reference>
  <reference>
    <citation>Sørensen SA, Fenger K. Causes of death in patients with Huntington's disease and in unaffected first degree relatives. J Med Genet. 1992 Dec;29(12):911-4.</citation>
    <PMID>1479606</PMID>
  </reference>
  <reference>
    <citation>Oliver JE. Huntington's chorea in Northamptonshire. Br J Psychiatry. 1970 Mar;116(532):241-53.</citation>
    <PMID>4244787</PMID>
  </reference>
  <reference>
    <citation>Greenamyre J, Shoulson I. Huntington's Disease. In: Calne D, ed. Neurodegenerative Diseases. Philadelphia: WB Saunders, 1994: 685-704.</citation>
  </reference>
  <reference>
    <citation>Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. Neurology. 1979 Jan;29(1):1-3.</citation>
    <PMID>154626</PMID>
  </reference>
  <reference>
    <citation>Feigin A, Kieburtz K, Bordwell K, Como P, Steinberg K, Sotack J, Zimmerman C, Hickey C, Orme C, Shoulson I. Functional decline in Huntington's disease. Mov Disord. 1995 Mar;10(2):211-4.</citation>
    <PMID>7753064</PMID>
  </reference>
  <reference>
    <citation>Myers RH, Sax DS, Koroshetz WJ, Mastromauro C, Cupples LA, Kiely DK, Pettengill FK, Bird ED. Factors associated with slow progression in Huntington's disease. Arch Neurol. 1991 Aug;48(8):800-4.</citation>
    <PMID>1832854</PMID>
  </reference>
  <reference>
    <citation>Penney JB Jr, Young AB, Shoulson I, Starosta-Rubenstein S, Snodgrass SR, Sanchez-Ramos J, Ramos-Arroyo M, Gomez F, Penchaszadeh G, Alvir J, et al. Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord. 1990;5(2):93-9.</citation>
    <PMID>2139171</PMID>
  </reference>
  <reference>
    <citation>Young AB, Penney JB, Starosta-Rubinstein S, Markel DS, Berent S, Giordani B, Ehrenkaufer R, Jewett D, Hichwa R. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol. 1986 Sep;20(3):296-303.</citation>
    <PMID>2945510</PMID>
  </reference>
  <reference>
    <citation>Kido D, Shoulson I, Manzione J, Harnish P. Measurement of caudate nucleus and putamen atrophy in patients with Huntington's disease. Neuroradiology 1991;33:604-606.</citation>
  </reference>
  <reference>
    <citation>Mazziotta JC. Huntington's disease: studies with structural imaging techniques and positron emission tomography. Semin Neurol. 1989 Dec;9(4):360-9. Review.</citation>
    <PMID>2534934</PMID>
  </reference>
  <reference>
    <citation>Beal MF, Ferrante RJ. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci. 2004 May;5(5):373-84. Review.</citation>
    <PMID>15100720</PMID>
  </reference>
  <reference>
    <citation>A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993 Mar 26;72(6):971-83.</citation>
    <PMID>8458085</PMID>
  </reference>
  <reference>
    <citation>Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, Bates G, Cooper JM, Schapira AH. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol. 2000 Jan;47(1):80-6.</citation>
    <PMID>10632104</PMID>
  </reference>
  <reference>
    <citation>Cha JH. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 2000 Sep;23(9):387-92. Review.</citation>
    <PMID>10941183</PMID>
  </reference>
  <reference>
    <citation>Ona VO, Li M, Vonsattel JP, Andrews LJ, Khan SQ, Chung WM, Frey AS, Menon AS, Li XJ, Stieg PE, Yuan J, Penney JB, Young AB, Cha JH, Friedlander RM. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature. 1999 May 20;399(6733):263-7.</citation>
    <PMID>10353249</PMID>
  </reference>
  <reference>
    <citation>Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000 Jul;6(7):797-801.</citation>
    <PMID>10888929</PMID>
  </reference>
  <reference>
    <citation>Beal MF, Hyman BT, Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci. 1993 Apr;16(4):125-31.</citation>
    <PMID>7682343</PMID>
  </reference>
  <reference>
    <citation>Wellington CL, Ellerby LM, Hackam AS, Margolis RL, Trifiro MA, Singaraja R, McCutcheon K, Salvesen GS, Propp SS, Bromm M, Rowland KJ, Zhang T, Rasper D, Roy S, Thornberry N, Pinsky L, Kakizuka A, Ross CA, Nicholson DW, Bredesen DE, Hayden MR. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem. 1998 Apr 10;273(15):9158-67.</citation>
    <PMID>9535906</PMID>
  </reference>
  <reference>
    <citation>Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7105-9.</citation>
    <PMID>7624378</PMID>
  </reference>
  <reference>
    <citation>Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol. 1996 Mar;39(3):385-9.</citation>
    <PMID>8602759</PMID>
  </reference>
  <reference>
    <citation>Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol. 1997 Feb;41(2):160-5.</citation>
    <PMID>9029064</PMID>
  </reference>
  <reference>
    <citation>Sawa A, Wiegand GW, Cooper J, Margolis RL, Sharp AH, Lawler JF Jr, Greenamyre JT, Snyder SH, Ross CA. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med. 1999 Oct;5(10):1194-8.</citation>
    <PMID>10502825</PMID>
  </reference>
  <reference>
    <citation>Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology. 1993 Dec;43(12):2689-95.</citation>
    <PMID>8255479</PMID>
  </reference>
  <reference>
    <citation>Lodi R, Schapira AH, Manners D, Styles P, Wood NW, Taylor DJ, Warner TT. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol. 2000 Jul;48(1):72-6.</citation>
    <PMID>10894218</PMID>
  </reference>
  <reference>
    <citation>Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci. 2002 Aug;5(8):731-6.</citation>
    <PMID>12089530</PMID>
  </reference>
  <reference>
    <citation>Gines S, Seong IS, Fossale E, Ivanova E, Trettel F, Gusella JF, Wheeler VC, Persichetti F, MacDonald ME. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum Mol Genet. 2003 Mar 1;12(5):497-508.</citation>
    <PMID>12588797</PMID>
  </reference>
  <reference>
    <citation>Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol. 1997 May;41(5):646-53.</citation>
    <PMID>9153527</PMID>
  </reference>
  <reference>
    <citation>Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci. 2000 Jun 15;20(12):4389-97.</citation>
    <PMID>10844007</PMID>
  </reference>
  <reference>
    <citation>Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci. 2002 Mar 1;22(5):1592-9.</citation>
    <PMID>11880489</PMID>
  </reference>
  <reference>
    <citation>Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF, Ferrante RJ. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem. 2003 Jun;85(6):1359-67.</citation>
    <PMID>12787055</PMID>
  </reference>
  <reference>
    <citation>Schilling G, Coonfield ML, Ross CA, Borchelt DR. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci Lett. 2001 Nov 27;315(3):149-53.</citation>
    <PMID>11716985</PMID>
  </reference>
  <reference>
    <citation>Matthews RT, Yang L, Browne S, Baik M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8892-7.</citation>
    <PMID>9671775</PMID>
  </reference>
  <reference>
    <citation>Beal MF, Henshaw DR, Jenkins BG, Rosen BR, Schulz JB. Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann Neurol. 1994 Dec;36(6):882-8.</citation>
    <PMID>7998775</PMID>
  </reference>
  <reference>
    <citation>Pepping J. Coenzyme Q10. Am J Health Syst Pharm. 1999 Mar 15;56(6):519-21. Review.</citation>
    <PMID>10192685</PMID>
  </reference>
  <reference>
    <citation>Musumeci O, Naini A, Slonim AE, Skavin N, Hadjigeorgiou GL, Krawiecki N, Weissman BM, Tsao CY, Mendell JR, Shanske S, De Vivo DC, Hirano M, DiMauro S. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology. 2001 Apr 10;56(7):849-55.</citation>
    <PMID>11294920</PMID>
  </reference>
  <reference>
    <citation>Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. 1995 May 24;1271(1):195-204. Review.</citation>
    <PMID>7599208</PMID>
  </reference>
  <reference>
    <citation>Yamagami T, Okishio T, Toyama S, Kishi T. Correlation of serum coenzyme Q10 level and leukocute complex II activity in nformal and cardiovascular patients. In: Folkers K, Yamagami T, eds. Biomedical and clinical aspects of coenzyme Q: Elsevier Science Publishers, 1981: 79-89.</citation>
  </reference>
  <reference>
    <citation>Söderberg M, Edlund C, Kristensson K, Dallner G. Lipid compositions of different regions of the human brain during aging. J Neurochem. 1990 Feb;54(2):415-23.</citation>
    <PMID>2299344</PMID>
  </reference>
  <reference>
    <citation>Peyser CE, Folstein M, Chase GA, Starkstein S, Brandt J, Cockrell JR, Bylsma F, Coyle JT, McHugh PR, Folstein SE. Trial of d-alpha-tocopherol in Huntington's disease. Am J Psychiatry. 1995 Dec;152(12):1771-5.</citation>
    <PMID>8526244</PMID>
  </reference>
  <reference>
    <citation>Ranen NG, Peyser CE, Coyle JT, Bylsma FW, Sherr M, Day L, Folstein MF, Brandt J, Ross CA, Folstein SE. A controlled trial of idebenone in Huntington's disease. Mov Disord. 1996 Sep;11(5):549-54.</citation>
    <PMID>8866496</PMID>
  </reference>
  <reference>
    <citation>Kremer B, Clark CM, Almqvist EW, Raymond LA, Graf P, Jacova C, Mezei M, Hardy MA, Snow B, Martin W, Hayden MR. Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology. 1999 Sep 22;53(5):1000-11.</citation>
    <PMID>10496259</PMID>
  </reference>
  <reference>
    <citation>Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, Hersch S, Vaddadi KS, Sword A, Horrobin DF, Manku M, Murck H. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology. 2005 Jul 26;65(2):286-92.</citation>
    <PMID>16043801</PMID>
  </reference>
  <reference>
    <citation>Dubois B, Brand M, Garcia de Yebenes J, et al. European-Huntington's-disease-Initiative (EHDI)-Trial: Objectives, design, and description of the study population at the end of inclusion. Mov Dis 2002;17:S319.</citation>
  </reference>
  <reference>
    <citation>Bogentoft C, Edelund P, Olsson B, Widlund L, Westensen K. Biopharmaceutical aspects of intraveneous and oral administration of coenzyme Q10. In: Folkers K, Littarru G, Yamagami T, eds. Biomedical and clinical aspects of coenzyme Q.: Elsevier Science Publishers, 1991: 215-224.</citation>
  </reference>
  <reference>
    <citation>Lucker P, Wetselsberg N, Hennings G, Rehn D. Pharmacokinetics of coenzyme ubidecarenone in healthy volunteers. In: Folkers K, Littarru G, Yamagami T, eds. Biomedical and clinical aspects of coenzyme Q: Elsevier Science Publishers, 1984: 143-151.</citation>
  </reference>
  <reference>
    <citation>Mohr D, Bowry VW, Stocker R. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochim Biophys Acta. 1992 Jun 26;1126(3):247-54.</citation>
    <PMID>1637852</PMID>
  </reference>
  <reference>
    <citation>Micromedex. Ubidecarenone drug monograph. Engelwood 1995 May; Update 1998 Mar.</citation>
  </reference>
  <reference>
    <citation>Zhang Y, Aberg F, Appelkvist EL, Dallner G, Ernster L. Uptake of dietary coenzyme Q supplement is limited in rats. J Nutr. 1995 Mar;125(3):446-53.</citation>
    <PMID>7876919</PMID>
  </reference>
  <reference>
    <citation>Weber C. Dietary intake and absorption of coenzyme Q. In: Kagan V, Quinn P, eds. Coenzyme Q: Molecular Mechanisms in Health and Disease. Boca Raton: CRC Press, 2001:209-215.</citation>
  </reference>
  <reference>
    <citation>Rundek T, Naini A, Sacco R, Coates K, DiMauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol. 2004 Jun;61(6):889-92.</citation>
    <PMID>15210526</PMID>
  </reference>
  <reference>
    <citation>Saito Y, Kubo H, Bujo H, Yamamoto Y. The changes in plasma coenzyme Q10 level during the statin therapy for hypercholesterolemic patients. In: Second Conference of the International Coenzyme Q10 Association.; 2000, 2000: 59.</citation>
  </reference>
  <reference>
    <citation>De Pinieux G, Chariot P, Ammi-Saïd M, Louarn F, Lejonc JL, Astier A, Jacotot B, Gherardi R. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol. 1996 Sep;42(3):333-7.</citation>
    <PMID>8877024</PMID>
  </reference>
  <reference>
    <citation>Watts GF, Castelluccio C, Rice-Evans C, Taub NA, Baum H, Quinn PJ. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol. 1993 Nov;46(11):1055-7.</citation>
    <PMID>8254097</PMID>
  </reference>
  <reference>
    <citation>Laaksonen R, Jokelainen K, Laakso J, Sahi T, Harkonen M, Tikkanen MJ, Himberg JJ. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol. 1996 Apr 15;77(10):851-4.</citation>
    <PMID>8623738</PMID>
  </reference>
  <reference>
    <citation>Huntington Study Group. Minocycline safety and tolerability in Huntington disease. Neurology. 2004 Aug 10;63(3):547-9.</citation>
    <PMID>15304592</PMID>
  </reference>
  <reference>
    <citation>Langsjoen H, Langsjoen P, Langsjoen P, Willis R, Folkers K. Usefulness of coenzyme Q10 in clinical cardiology: a long-term study. Mol Aspects Med. 1994;15 Suppl:s165-75.</citation>
    <PMID>7752828</PMID>
  </reference>
  <reference>
    <citation>Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci U S A. 1989 Apr;86(7):2379-82.</citation>
    <PMID>2928337</PMID>
  </reference>
  <reference>
    <citation>Di Giovanni S, Mirabella M, Spinazzola A, Crociani P, Silvestri G, Broccolini A, Tonali P, Di Mauro S, Servidei S. Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. Neurology. 2001 Aug 14;57(3):515-8.</citation>
    <PMID>11502923</PMID>
  </reference>
  <reference>
    <citation>Lodi R, Hart PE, Rajagopalan B, Taylor DJ, Crilley JG, Bradley JL, Blamire AM, Manners D, Styles P, Schapira AH, Cooper JM. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann Neurol. 2001 May;49(5):590-6.</citation>
    <PMID>11357949</PMID>
  </reference>
  <reference>
    <citation>Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M; Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002 Oct;59(10):1541-50.</citation>
    <PMID>12374491</PMID>
  </reference>
  <reference>
    <citation>Shults CW, Flint Beal M, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol. 2004 Aug;188(2):491-4.</citation>
    <PMID>15246848</PMID>
  </reference>
  <reference>
    <citation>Greenberg S, Frishman WH. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol. 1990 Jul;30(7):596-608. Review.</citation>
    <PMID>2202752</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2008</study_first_submitted>
  <study_first_submitted_qc>February 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <results_first_submitted>December 7, 2015</results_first_submitted>
  <results_first_submitted_qc>February 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 30, 2016</results_first_posted>
  <last_update_submitted>February 29, 2016</last_update_submitted>
  <last_update_submitted_qc>February 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Merit E. Cudkowicz, MD</investigator_full_name>
    <investigator_title>Julieanne Dorn Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Huntington's disease</keyword>
  <keyword>Huntington disease</keyword>
  <keyword>HD</keyword>
  <keyword>coenzyme Q10</keyword>
  <keyword>CoQ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>A - Coenzyme Q10 2400 mg/Day</title>
          <description>Randomized to active treatment (coenzyme Q10 2400 mg/day)
coenzyme Q10: 4 - 300 mg CoQ chewable wafers taken orally twice a day</description>
        </group>
        <group group_id="P2">
          <title>B - Placebo</title>
          <description>Randomized to placebo
placebo: an inactive substance</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="303"/>
                <participants group_id="P2" count="306"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="224"/>
                <participants group_id="P2" count="240"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Institutionalized</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A - Coenzyme Q10 2400 mg/Day</title>
          <description>Randomized to active treatment (coenzyme Q10 2400 mg/day)
coenzyme Q10: 4 - 300 mg CoQ chewable wafers taken orally twice a day</description>
        </group>
        <group group_id="B2">
          <title>B - Placebo</title>
          <description>Randomized to placebo
placebo: an inactive substance</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="303"/>
            <count group_id="B2" value="306"/>
            <count group_id="B3" value="609"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.5" spread="11.9"/>
                    <measurement group_id="B2" value="50.7" spread="11.6"/>
                    <measurement group_id="B3" value="50.6" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Joint Rank (Combination of Time to Death (for Subjects Who Died) and Change in Total Functional Capacity Score (TFC) From Baseline to Month 60 (for Subjects Who Survived))</title>
        <description>The primary outcome variable at the start of the trial was the change in TFC score from baseline to Month 60. The Data and Safety Monitoring Board recommended to the trial leadership that they reconsider how they accommodate missing data from subjects who die in their primary analysis of the change in TFC score. Based on these recommendations, the trial leadership changed the primary analysis to that of a joint rank approach. TFC consists of five ordinally scaled items assessing a person’s capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best).</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - Coenzyme Q10 2400 mg/Day</title>
            <description>Randomized to active treatment (coenzyme Q10 2400 mg/day)
coenzyme Q10: 4 - 300 mg CoQ chewable wafers taken orally twice a day</description>
          </group>
          <group group_id="O2">
            <title>B - Placebo</title>
            <description>Randomized to placebo
placebo: an inactive substance</description>
          </group>
        </group_list>
        <measure>
          <title>Joint Rank (Combination of Time to Death (for Subjects Who Died) and Change in Total Functional Capacity Score (TFC) From Baseline to Month 60 (for Subjects Who Survived))</title>
          <description>The primary outcome variable at the start of the trial was the change in TFC score from baseline to Month 60. The Data and Safety Monitoring Board recommended to the trial leadership that they reconsider how they accommodate missing data from subjects who die in their primary analysis of the change in TFC score. Based on these recommendations, the trial leadership changed the primary analysis to that of a joint rank approach. TFC consists of five ordinally scaled items assessing a person’s capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best).</description>
          <units>rank</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303.3" spread="173.1"/>
                    <measurement group_id="O2" value="306.7" spread="179.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>In this joint rank analysis, subjects are ranked from worst to best outcome with subjects who die being assigned the worst ranks (and ranked according to the time of death) and subjects who survive being ranked more favorably in the order of the change from baseline to Month 60 in TFC score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>π hat</param_type>
            <param_value>0.494</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.454</ci_lower_limit>
            <ci_upper_limit>0.534</ci_upper_limit>
            <estimate_desc>π hat is the estimate of the probability π that a randomly selected subject treated with CoQ has a better outcome than a randomly selected subject treated with placebo. Under the null hypothesis of no effect of CoQ, π = 0.50.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Functional Capacity (TFC) Score From Baseline to Month 60</title>
        <description>TFC consists of five ordinally scaled items assessing a person’s capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best).</description>
        <time_frame>Baseline and Month 60</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - Coenzyme Q10 2400 mg/Day</title>
            <description>Randomized to active treatment (coenzyme Q10 2400 mg/day)
coenzyme Q10: 4 - 300 mg CoQ chewable wafers taken orally twice a day</description>
          </group>
          <group group_id="O2">
            <title>B - Placebo</title>
            <description>Randomized to placebo
placebo: an inactive substance</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Functional Capacity (TFC) Score From Baseline to Month 60</title>
          <description>TFC consists of five ordinally scaled items assessing a person’s capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best).</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.53" spread="0.25"/>
                    <measurement group_id="O2" value="-4.76" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Functional Checklist Score From Baseline to Month 60</title>
        <description>The functional assessment checklist includes 25 questions about common daily tasks. A score of 1 is given for each &quot;yes&quot; reply and a score of 0 is given for each &quot;no&quot; reply (scale range is 0-25). Higher scores indicate better functioning.</description>
        <time_frame>Baseline and Month 60</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - Coenzyme Q10 2400 mg/Day</title>
            <description>Randomized to active treatment (coenzyme Q10 2400 mg/day)
coenzyme Q10: 4 - 300 mg CoQ chewable wafers taken orally twice a day</description>
          </group>
          <group group_id="O2">
            <title>B - Placebo</title>
            <description>Randomized to placebo
placebo: an inactive substance</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Checklist Score From Baseline to Month 60</title>
          <description>The functional assessment checklist includes 25 questions about common daily tasks. A score of 1 is given for each &quot;yes&quot; reply and a score of 0 is given for each &quot;no&quot; reply (scale range is 0-25). Higher scores indicate better functioning.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.93" spread="0.55"/>
                    <measurement group_id="O2" value="-8.02" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.40</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Independence Scale Score From Baseline to Month 60</title>
        <description>The independence scale assesses independence on a 0 to 100 scale with higher scores indicating better functioning.</description>
        <time_frame>Baseline and Month 60</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - Coenzyme Q10 2400 mg/Day</title>
            <description>Randomized to active treatment (coenzyme Q10 2400 mg/day)
coenzyme Q10: 4 - 300 mg CoQ chewable wafers taken orally twice a day</description>
          </group>
          <group group_id="O2">
            <title>B - Placebo</title>
            <description>Randomized to placebo
placebo: an inactive substance</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Independence Scale Score From Baseline to Month 60</title>
          <description>The independence scale assesses independence on a 0 to 100 scale with higher scores indicating better functioning.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.30" spread="1.92"/>
                    <measurement group_id="O2" value="-24.86" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.68</ci_lower_limit>
            <ci_upper_limit>3.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Motor Score From Baseline to Month 60</title>
        <description>The motor section of the Unified Huntington's Disease Rating Scale (UHDRS) assesses motor features of Huntington disease with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor score is the sum of all the individual motor ratings, with higher scores (124) indicating more severe motor impairment than lower scores. The score ranges from 0 to 124.</description>
        <time_frame>Baseline and Month 60</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - Coenzyme Q10 2400 mg/Day</title>
            <description>Randomized to active treatment (coenzyme Q10 2400 mg/day)
coenzyme Q10: 4 - 300 mg CoQ chewable wafers taken orally twice a day</description>
          </group>
          <group group_id="O2">
            <title>B - Placebo</title>
            <description>Randomized to placebo
placebo: an inactive substance</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Motor Score From Baseline to Month 60</title>
          <description>The motor section of the Unified Huntington's Disease Rating Scale (UHDRS) assesses motor features of Huntington disease with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor score is the sum of all the individual motor ratings, with higher scores (124) indicating more severe motor impairment than lower scores. The score ranges from 0 to 124.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.06" spread="1.22"/>
                    <measurement group_id="O2" value="19.18" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.40</ci_lower_limit>
            <ci_upper_limit>2.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Behavioral Frequency Score From Baseline to Month 60</title>
        <description>The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. A total score was calculated by summing up all the individual behavioral frequency items (range 0-56) with higher scores representing more severe behavioral impairment.</description>
        <time_frame>Baseline and Month 60</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - Coenzyme Q10 2400 mg/Day</title>
            <description>Randomized to active treatment (coenzyme Q10 2400 mg/day)
coenzyme Q10: 4 - 300 mg CoQ chewable wafers taken orally twice a day</description>
          </group>
          <group group_id="O2">
            <title>B - Placebo</title>
            <description>Randomized to placebo
placebo: an inactive substance</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Behavioral Frequency Score From Baseline to Month 60</title>
          <description>The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. A total score was calculated by summing up all the individual behavioral frequency items (range 0-56) with higher scores representing more severe behavioral impairment.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.55"/>
                    <measurement group_id="O2" value="1.43" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.48</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Behavioral Frequency x Severity Score From Baseline to Month 60</title>
        <description>The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. The total score is the sum of the product of the individual behavioral frequency and severity items (range 0-176) with higher scores representing more severe behavioral impairment.</description>
        <time_frame>Baseline and Month 60</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - Coenzyme Q10 2400 mg/Day</title>
            <description>Randomized to active treatment (coenzyme Q10 2400 mg/day)
coenzyme Q10: 4 - 300 mg CoQ chewable wafers taken orally twice a day</description>
          </group>
          <group group_id="O2">
            <title>B - Placebo</title>
            <description>Randomized to placebo
placebo: an inactive substance</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Behavioral Frequency x Severity Score From Baseline to Month 60</title>
          <description>The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. The total score is the sum of the product of the individual behavioral frequency and severity items (range 0-176) with higher scores representing more severe behavioral impairment.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.29" spread="1.52"/>
                    <measurement group_id="O2" value="5.06" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.78</ci_lower_limit>
            <ci_upper_limit>3.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Symbol Digit Modalities Test (SDMT) From Baseline to Month 60</title>
        <description>The SDMT assesses attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The score is the number of correctly paired abstract symbols and specific numbers in 90 seconds with higher scores indicating better cognitive functioning.</description>
        <time_frame>Baseline and Month 60</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - Coenzyme Q10 2400 mg/Day</title>
            <description>Randomized to active treatment (coenzyme Q10 2400 mg/day)
coenzyme Q10: 4 - 300 mg CoQ chewable wafers taken orally twice a day</description>
          </group>
          <group group_id="O2">
            <title>B - Placebo</title>
            <description>Randomized to placebo
placebo: an inactive substance</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Symbol Digit Modalities Test (SDMT) From Baseline to Month 60</title>
          <description>The SDMT assesses attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The score is the number of correctly paired abstract symbols and specific numbers in 90 seconds with higher scores indicating better cognitive functioning.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.95" spread="0.66"/>
                    <measurement group_id="O2" value="-11.36" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.32</ci_lower_limit>
            <ci_upper_limit>2.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Verbal Fluency Test From Baseline to Month 60</title>
        <description>The verbal fluency test is typically considered a measure of executive function. The score is the number of correct words produced across three 1-minute trials.</description>
        <time_frame>Baseline and Month 60</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - Coenzyme Q10 2400 mg/Day</title>
            <description>Randomized to active treatment (coenzyme Q10 2400 mg/day)
coenzyme Q10: 4 - 300 mg CoQ chewable wafers taken orally twice a day</description>
          </group>
          <group group_id="O2">
            <title>B - Placebo</title>
            <description>Randomized to placebo
placebo: an inactive substance</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Verbal Fluency Test From Baseline to Month 60</title>
          <description>The verbal fluency test is typically considered a measure of executive function. The score is the number of correct words produced across three 1-minute trials.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.07" spread="0.79"/>
                    <measurement group_id="O2" value="-4.47" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.71</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Stroop Interference Test - Color Naming From Baseline to Month 60</title>
        <description>Stroop Interference Test - color naming score is the total number of correct colors identified in 45 seconds and reflects processing speed.</description>
        <time_frame>Baseline and Month 60</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - Coenzyme Q10 2400 mg/Day</title>
            <description>Randomized to active treatment (coenzyme Q10 2400 mg/day)
coenzyme Q10: 4 - 300 mg CoQ chewable wafers taken orally twice a day</description>
          </group>
          <group group_id="O2">
            <title>B - Placebo</title>
            <description>Randomized to placebo
placebo: an inactive substance</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Stroop Interference Test - Color Naming From Baseline to Month 60</title>
          <description>Stroop Interference Test - color naming score is the total number of correct colors identified in 45 seconds and reflects processing speed.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.21" spread="1.00"/>
                    <measurement group_id="O2" value="-14.51" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.28</ci_lower_limit>
            <ci_upper_limit>2.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Stroop Interference Test - Word Reading From Baseline to Month 60</title>
        <description>Stroop Interference Test - word reading score is the total number of correct words read in 45 seconds and reflects processing speed.</description>
        <time_frame>Baseline and Month 60</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - Coenzyme Q10 2400 mg/Day</title>
            <description>Randomized to active treatment (coenzyme Q10 2400 mg/day)
coenzyme Q10: 4 - 300 mg CoQ chewable wafers taken orally twice a day</description>
          </group>
          <group group_id="O2">
            <title>B - Placebo</title>
            <description>Randomized to placebo
placebo: an inactive substance</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Stroop Interference Test - Word Reading From Baseline to Month 60</title>
          <description>Stroop Interference Test - word reading score is the total number of correct words read in 45 seconds and reflects processing speed.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.25" spread="1.36"/>
                    <measurement group_id="O2" value="-19.13" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>7.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Stroop Interference Test - Interference From Baseline to Month 60</title>
        <description>Stroop Interference Test - interference score is the total number of correct items identified in 45 seconds and reflects an executive measure of inhibitory ability.</description>
        <time_frame>Baseline and Month 60</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - Coenzyme Q10 2400 mg/Day</title>
            <description>Randomized to active treatment (coenzyme Q10 2400 mg/day)
coenzyme Q10: 4 - 300 mg CoQ chewable wafers taken orally twice a day</description>
          </group>
          <group group_id="O2">
            <title>B - Placebo</title>
            <description>Randomized to placebo
placebo: an inactive substance</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Stroop Interference Test - Interference From Baseline to Month 60</title>
          <description>Stroop Interference Test - interference score is the total number of correct items identified in 45 seconds and reflects an executive measure of inhibitory ability.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.57" spread="0.81"/>
                    <measurement group_id="O2" value="-8.61" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.10</ci_lower_limit>
            <ci_upper_limit>3.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to a Two-Point Decline in TFC Score or Death</title>
        <description>TFC consists of five ordinally scaled items assessing a person’s capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best).</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - Coenzyme Q10 2400 mg/Day</title>
            <description>Randomized to active treatment (coenzyme Q10 2400 mg/day)
coenzyme Q10: 4 - 300 mg CoQ chewable wafers taken orally twice a day</description>
          </group>
          <group group_id="O2">
            <title>B - Placebo</title>
            <description>Randomized to placebo
placebo: an inactive substance</description>
          </group>
        </group_list>
        <measure>
          <title>Time to a Two-Point Decline in TFC Score or Death</title>
          <description>TFC consists of five ordinally scaled items assessing a person’s capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best).</description>
          <units>days to event</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="553" lower_limit="545" upper_limit="728"/>
                    <measurement group_id="O2" value="549" lower_limit="395" upper_limit="726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to a Three-Point Decline in TFC Score or Death</title>
        <description>TFC consists of five ordinally scaled items assessing a person’s capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best).</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - Coenzyme Q10 2400 mg/Day</title>
            <description>Randomized to active treatment (coenzyme Q10 2400 mg/day)
coenzyme Q10: 4 - 300 mg CoQ chewable wafers taken orally twice a day</description>
          </group>
          <group group_id="O2">
            <title>B - Placebo</title>
            <description>Randomized to placebo
placebo: an inactive substance</description>
          </group>
        </group_list>
        <measure>
          <title>Time to a Three-Point Decline in TFC Score or Death</title>
          <description>TFC consists of five ordinally scaled items assessing a person’s capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best).</description>
          <units>days to event</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="917" lower_limit="760" upper_limit="1092"/>
                    <measurement group_id="O2" value="911" lower_limit="737" upper_limit="1092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number Completing Study at Assigned Dosage Level</title>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - Coenzyme Q10 2400 mg/Day</title>
            <description>Randomized to active treatment (coenzyme Q10 2400 mg/day)
coenzyme Q10: 4 - 300 mg CoQ chewable wafers taken orally twice a day</description>
          </group>
          <group group_id="O2">
            <title>B - Placebo</title>
            <description>Randomized to placebo
placebo: an inactive substance</description>
          </group>
        </group_list>
        <measure>
          <title>Number Completing Study at Assigned Dosage Level</title>
          <units>participants completing study on drug</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <desc>Adverse events were assessed at each visit by recording all voluntary complaints of the subject and by assessment of clinical features. Subjects were questioned regarding the occurrence of any adverse event since the last visit. All adverse events were recorded on an Adverse Event Log case report form.</desc>
      <group_list>
        <group group_id="E1">
          <title>A - Coenzyme Q10 2400 mg/Day</title>
          <description>Randomized to active treatment (coenzyme Q10 2400 mg/day)
coenzyme Q10: 4 - 300 mg CoQ chewable wafers taken orally twice a day</description>
        </group>
        <group group_id="E2">
          <title>B - Placebo</title>
          <description>Randomized to placebo
placebo: an inactive substance</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>HUNTINGTON`S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>CROHN`S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>PEPTIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>DRUG WITHDRAWAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>ARTHRITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>NECROTISING FASCIITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>SKIN GRAFT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACCIDENTAL OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>COMMINUTED FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>FIBULA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>INTENTIONAL OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>LIMB TRAUMATIC AMPUTATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>TIBIA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>TRAUMATIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>NOSE DEFORMITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>OSTEOPOROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>RHABDOMYOLYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>BRAIN NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>CARCINOID TUMOUR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>COLON CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>GLIOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>INFLAMMATORY CARCINOMA OF THE BREAST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>MANTLE CELL LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>CHOREA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE INTRACRANIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>PARKINSONISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>TOXIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ABNORMAL BEHAVIOUR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>AGGRESSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>AGITATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>COMPLETED SUICIDE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>DELUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>HALLUCINATION, AUDITORY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>MAJOR DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>PANIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>PARANOIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>PSYCHOTIC BEHAVIOUR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>PSYCHOTIC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>SUICIDAL BEHAVIOUR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>UTERINE PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>BRONCHIECTASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>UPPER AIRWAY OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>CORONARY ARTERY BYPASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>DEEP BRAIN STIMULATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>HAEMORRHOID OPERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>HERNIA REPAIR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>HIP ARTHROPLASTY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>HYSTERECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>KNEE ARTHROPLASTY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>SHOULDER ARTHROPLASTY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>SPINAL LAMINECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>SURGERY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>THYROIDECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>ILIAC ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="276" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="280" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>BALANCE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>CHOREA</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>An interim analysis for futility revealed a conditional power of &lt; 5% for the primary analysis, and the trial was halted in July, 2014. Only data collected prior to this time were included in the final analyses.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Merit Cudkowicz</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-0813</phone>
      <email>mcudkowicz@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

